Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.
Identifieur interne : 000744 ( PubMed/Corpus ); précédent : 000743; suivant : 000745Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.
Auteurs : Tiago A. Mestre ; Tiago Teodoro ; William Reginold ; Julia Graf ; Maike Kasten ; Joanna Sale ; Mateusz Zurowski ; Janis Miyasaki ; Joaquim J. Ferreira ; Connie MarrasSource :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease, Physicians.
- Aged, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Physician-Patient Relations, Practice Patterns, Physicians', Surveys and Questionnaires.
Abstract
Reluctance to start medication has never been investigated before in PD. We studied reluctance to start medication for PD motor symptoms, namely its prevalence, underlying reasons, drug-specificity, and associated delay in the start of PD medication. A cross-sectional observational international study was conducted. Patients with a clinical diagnosis of PD advised to start antiparkinsonian medication in the previous 5 years were invited to complete a questionnaire in three centers located in North America and Europe. An electronic online survey was sent to physicians through the mailing list of the Movement Disorder Society. 469 participants (201 PD patients, 268 physicians). 40.2% (n = 82) of the patients reported reluctance to start medication, but 88.6% (n = 234/264) of the physicians estimated that ≤20% of their patients with PD had been reluctant to start medication. The most common reasons reported by patients were the fear of side effects (n = 35, 55.6%), followed by non-acceptance of diagnosis (n = 23, 36.5%); fear of a temporally limited benefit was more commonly selected by physicians (n = 92/267, 34.5%). Patients indicated reluctance to start DAs more frequently compared with L-DOPA (OR: 2.22, 95% CI: 1.30, 9.03; p = 0.013) while physicians perceived L-DOPA to be associated with more reluctance (OR: 4.7, 95% CI: 3.41; 6.59; p < 0.0001). Patients with PD and physicians have a different perspective on the issue of reluctance to start medication. There is a need to bring physicians and patients with PD closer to a shared vision of the problem reluctance to start medication.
DOI: 10.1016/j.parkreldis.2014.03.001
PubMed: 24661467
Links to Exploration step
pubmed:24661467Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.</title><author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada. Electronic address: tmestre@toh.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Teodoro, Tiago" sort="Teodoro, Tiago" uniqKey="Teodoro T" first="Tiago" last="Teodoro">Tiago Teodoro</name><affiliation><nlm:affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Reginold, William" sort="Reginold, William" uniqKey="Reginold W" first="William" last="Reginold">William Reginold</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Graf, Julia" sort="Graf, Julia" uniqKey="Graf J" first="Julia" last="Graf">Julia Graf</name><affiliation><nlm:affiliation>Institute of Neurogenetics, University of Luebeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kasten, Maike" sort="Kasten, Maike" uniqKey="Kasten M" first="Maike" last="Kasten">Maike Kasten</name><affiliation><nlm:affiliation>Institute of Neurogenetics, University of Luebeck, Germany; Department of Psychiatry and Psychotherapy, University of Luebeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sale, Joanna" sort="Sale, Joanna" uniqKey="Sale J" first="Joanna" last="Sale">Joanna Sale</name><affiliation><nlm:affiliation>Mobility Program Clinical Research Unit, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada; Department of Psychiatry, Toronto Western Hospital, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation><nlm:affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24661467</idno><idno type="pmid">24661467</idno><idno type="doi">10.1016/j.parkreldis.2014.03.001</idno><idno type="wicri:Area/PubMed/Corpus">000744</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000744</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.</title><author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada. Electronic address: tmestre@toh.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Teodoro, Tiago" sort="Teodoro, Tiago" uniqKey="Teodoro T" first="Tiago" last="Teodoro">Tiago Teodoro</name><affiliation><nlm:affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Reginold, William" sort="Reginold, William" uniqKey="Reginold W" first="William" last="Reginold">William Reginold</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Graf, Julia" sort="Graf, Julia" uniqKey="Graf J" first="Julia" last="Graf">Julia Graf</name><affiliation><nlm:affiliation>Institute of Neurogenetics, University of Luebeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kasten, Maike" sort="Kasten, Maike" uniqKey="Kasten M" first="Maike" last="Kasten">Maike Kasten</name><affiliation><nlm:affiliation>Institute of Neurogenetics, University of Luebeck, Germany; Department of Psychiatry and Psychotherapy, University of Luebeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sale, Joanna" sort="Sale, Joanna" uniqKey="Sale J" first="Joanna" last="Sale">Joanna Sale</name><affiliation><nlm:affiliation>Mobility Program Clinical Research Unit, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada; Department of Psychiatry, Toronto Western Hospital, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation><nlm:affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><nlm:affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Physician-Patient Relations</term><term>Physicians (psychology)</term><term>Practice Patterns, Physicians'</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term><term>Physicians</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Physician-Patient Relations</term><term>Practice Patterns, Physicians'</term><term>Surveys and Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reluctance to start medication has never been investigated before in PD. We studied reluctance to start medication for PD motor symptoms, namely its prevalence, underlying reasons, drug-specificity, and associated delay in the start of PD medication. A cross-sectional observational international study was conducted. Patients with a clinical diagnosis of PD advised to start antiparkinsonian medication in the previous 5 years were invited to complete a questionnaire in three centers located in North America and Europe. An electronic online survey was sent to physicians through the mailing list of the Movement Disorder Society. 469 participants (201 PD patients, 268 physicians). 40.2% (n = 82) of the patients reported reluctance to start medication, but 88.6% (n = 234/264) of the physicians estimated that ≤20% of their patients with PD had been reluctant to start medication. The most common reasons reported by patients were the fear of side effects (n = 35, 55.6%), followed by non-acceptance of diagnosis (n = 23, 36.5%); fear of a temporally limited benefit was more commonly selected by physicians (n = 92/267, 34.5%). Patients indicated reluctance to start DAs more frequently compared with L-DOPA (OR: 2.22, 95% CI: 1.30, 9.03; p = 0.013) while physicians perceived L-DOPA to be associated with more reluctance (OR: 4.7, 95% CI: 3.41; 6.59; p < 0.0001). Patients with PD and physicians have a different perspective on the issue of reluctance to start medication. There is a need to bring physicians and patients with PD closer to a shared vision of the problem reluctance to start medication.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24661467</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>19</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Parkinsonism & related disorders</Title><ISOAbbreviation>Parkinsonism Relat. Disord.</ISOAbbreviation></Journal><ArticleTitle>Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.</ArticleTitle><Pagination><MedlinePgn>608-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.parkreldis.2014.03.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1353-8020(14)00083-2</ELocationID><Abstract><AbstractText>Reluctance to start medication has never been investigated before in PD. We studied reluctance to start medication for PD motor symptoms, namely its prevalence, underlying reasons, drug-specificity, and associated delay in the start of PD medication. A cross-sectional observational international study was conducted. Patients with a clinical diagnosis of PD advised to start antiparkinsonian medication in the previous 5 years were invited to complete a questionnaire in three centers located in North America and Europe. An electronic online survey was sent to physicians through the mailing list of the Movement Disorder Society. 469 participants (201 PD patients, 268 physicians). 40.2% (n = 82) of the patients reported reluctance to start medication, but 88.6% (n = 234/264) of the physicians estimated that ≤20% of their patients with PD had been reluctant to start medication. The most common reasons reported by patients were the fear of side effects (n = 35, 55.6%), followed by non-acceptance of diagnosis (n = 23, 36.5%); fear of a temporally limited benefit was more commonly selected by physicians (n = 92/267, 34.5%). Patients indicated reluctance to start DAs more frequently compared with L-DOPA (OR: 2.22, 95% CI: 1.30, 9.03; p = 0.013) while physicians perceived L-DOPA to be associated with more reluctance (OR: 4.7, 95% CI: 3.41; 6.59; p < 0.0001). Patients with PD and physicians have a different perspective on the issue of reluctance to start medication. There is a need to bring physicians and patients with PD closer to a shared vision of the problem reluctance to start medication.</AbstractText><CopyrightInformation>Copyright © 2014. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Tiago A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada. Electronic address: tmestre@toh.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Tiago</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reginold</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurogenetics, University of Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurogenetics, University of Luebeck, Germany; Department of Psychiatry and Psychotherapy, University of Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sale</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mobility Program Clinical Research Unit, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurowski</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada; Department of Psychiatry, Toronto Western Hospital, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Joaquim J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marras</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre and The Edmond J. Safra Program in Parkinson's disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC-7 402, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="Y">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="N">Physicians</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Reluctance</Keyword><Keyword MajorTopicYN="N">Treatment initiation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24661467</ArticleId><ArticleId IdType="pii">S1353-8020(14)00083-2</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2014.03.001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000744 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000744 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24661467
|texte= Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24661467" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |